Skip to main content
TipRanks
Go Ultimate75% OFF

Compare Piu Medical S.P.A. (PMED) vs. Competitors

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
IT:PMEDPiu Medical S.P.A.EUR 5.50EUR 39.51M―-5.25%Moderate BuyUnlock the IT:PMED analyst price target with TipRanks PremiumIT:PMEDUnlock the IT:PMED top-analyst price target with TipRanks Premium
IT:GHCGarofalo Health Care S.P.A.EUR 5.20EUR 466.86M23.970.00%Moderate BuyUnlock the IT:GHC analyst price target with TipRanks PremiumIT:PMED vs IT:GHCUnlock the IT:GHC top-analyst price target with TipRanks Premium
IT:GPIGPI SpAEUR 15.10EUR 434.94M26.49-0.79%Moderate BuyUnlock the IT:GPI analyst price target with TipRanks PremiumIT:PMED vs IT:GPIUnlock the IT:GPI top-analyst price target with TipRanks Premium
IT:SVSSvas Biosana S.p.A.EUR 8.00EUR 42.74M6.63-3.61%Moderate BuyUnlock the IT:SVS analyst price target with TipRanks PremiumIT:PMED vs IT:SVSUnlock the IT:SVS top-analyst price target with TipRanks Premium
IT:IMDI.M.D. International Medical Devices S.P.A.EUR 1.17EUR 20.27M16.14-19.31%―Unlock the IT:IMD analyst price target with TipRanks PremiumIT:PMED vs IT:IMDUnlock the IT:IMD top-analyst price target with TipRanks Premium
IT:OTOOtofarma S.P.A.EUR 2.34EUR 13.92M-14.48-53.75%―Unlock the IT:OTO analyst price target with TipRanks PremiumIT:PMED vs IT:OTOUnlock the IT:OTO top-analyst price target with TipRanks Premium

Performance Comparison

-60%-40%-20%0%20%40%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
IT:PMEDPiu Medical S.P.A.5.50-0.30-5.25%
IT:GHCGarofalo Health Care S.P.A.5.200.152.99%
IT:GPIGPI SpA15.100.926.47%
IT:SVSSvas Biosana S.p.A.8.00-0.21-2.61%
IT:IMDI.M.D. International Medical Devices S.P.A.1.17-0.21-15.34%
IT:OTOOtofarma S.P.A.2.34-2.72-53.75%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts